1. Home
  2. DERM vs HURA Comparison

DERM vs HURA Comparison

Compare DERM & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

HOLD

Current Price

$6.49

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.13

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DERM
HURA
Founded
2014
2009
Country
United States
United States
Employees
N/A
22
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
160.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DERM
HURA
Price
$6.49
$2.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$12.67
$9.50
AVG Volume (30 Days)
144.4K
252.3K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
N/A
EPS
N/A
N/A
Revenue
$61,858,000.00
N/A
Revenue This Year
$39.72
N/A
Revenue Next Year
$63.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.20
N/A
52 Week Low
$4.31
$0.41
52 Week High
$9.56
$3.90

Technical Indicators

Market Signals
Indicator
DERM
HURA
Relative Strength Index (RSI) 48.83 44.17
Support Level $5.85 $2.11
Resistance Level $6.59 $2.20
Average True Range (ATR) 0.33 0.10
MACD -0.05 -0.01
Stochastic Oscillator 39.26 39.34

Price Performance

Historical Comparison
DERM
HURA

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: